国际皮肤性病学杂志    2003 29 (3): 161-163   ISSN: 2096-5540  CN: 32-1880/R   白癜风的HLA等位基因研究进展 瞿镔, 许爱娥 杭州市第三人民医院皮肤科, 310009 收稿日期 2002-09-09  修回日期 null  网络版发布日期 null 参考文献  [1] Kemp EH, Waterman EA, Hawes BE, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest, 2002, 109 (7):923-930. [2] van den Wijngaard R, Wankowicz-Kalinska A, Pals S, et al. Autoimmune melanocyte destruction in vitiligo. Lab Invest, 2001, 81 (8):1061-1067. [3] Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol, 2001, 2(3):167-181. [4] Kim SM, Chung HS, Hann SK. The genetics of vitiligo in Korean patients. Int J Dermatol, 1998, 37(12):908-910. [5] Arcos-Burgos M, Parodi E, Salgar M, et al. Vitiligo:complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. Hum Genet, 2002, 110(4):334-342. [6] Boisseau-Garsaud AM, Saint-Cyr I, Quist D, et al. Familial aggregation of vitiligo in the French West Indies (Isle of Martinique). Eur J Dermatol, 2001, 11(6):554-556. [7] Robinson J, Waller MJ, Parham P,et al. IMGT/HLA Database-a sequence database for the human major histocompatibility complex. Nucleic Acids Res, 2001,29(1):210-213. [8] Little AM, Pasham P. Polymorphism and evolution of HLA class I and Ⅱ genes and molecules. Rev Immunogenet, 1999, 1 (1):105-123. [9] The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility complex. Nature, 1999, 401(6756):921-923. [10] Bue M, Busova B, Hegyi E,et al. Vitiligo is associated with HLA-A2and HLA-Dw7 in the Slovak populations. Folia Biol (Praha), 1996,42(1-2):23-25. [11] Lorini R, Orecchia G, Martinetti M, et al. Autoimmunity in vitiligo:relationship with HLA, Gm and Km polymorphisms. Autoimmunity,1992, 11 (4):255-260. [12] Orecchia G, Perfetti L, Malagoli P, et al. Vitiligo is associated with a significant increase in HLA-A30, Cw6 and DQw3 and a decrease in C4AQ0 in northern Italian patients. Dermatology, 1992, 185 (2):123-127. [13] Ando I, Chi HI, Nakagawa H, et al. Difference in clinical features and HLA antigens between familial and non-familial vitiligo of non-segmental type. Br J Dermatol, 1993, 129(4):408-410. [14] al-Fouzan A, al-Arbash M, Fouad F,et al. Study of HLA class I/IL and T lymphocyte subsets in Kuwaiti vitiligo patients. Eur J Immunogenet, 1995, 22(2):209-213. [15] Venkataram MN, White AG, Leeny WA,et al. HLA antigens in Omani patients with vitiligo. Clin Exp Dermatol, 1995, 20(1):35-37. [16] Schallreuter KU, Levenig C, Kuhnl P, et al. Histocompatibility antigens in vitiligo:Hamburg study on 102 patients from northern Germany. Dermatology, 1993, 187 (3):186-192. [17] Venneker GT, de Waal LP, Westerhof W, et al. HLA associations in vitiligo patients in the Dutch population. Dis Markers, 1993, 11 (4):187-190. [18] Buc M, Fazekasova H, Cechova E, et al. Occurrence rates of HLADRB1, HLA-DQB1, and HLA-DPB1 alleles in patients suffering from vitiligo. Eur J Dermatol, 1998, 8(1):13-15. [19] Zamani M, Spaepen M, Sghar SS, et al. Linkage and association of HLA class Ⅱ genes with vitiligo in a Dutch population. Br J Dermatol,2001, 145(1):90-94. [20] Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo:imbalance of epidermal eytokines at sites of lesions.Pigment Cell Res, 2002, 15(2):87-92. 通讯作者: